Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prevention of pulmonary hypoplasia and pulmonary vascular remodeling by antenatal simvastatin treatment in nitrofen-induced congenital diaphragmatic hernia.
Makanga M, Maruyama H, Dewachter C, Da Costa AM, Hupkens E, de Medina G, Naeije R, Dewachter L. Makanga M, et al. Am J Physiol Lung Cell Mol Physiol. 2015 Apr 1;308(7):L672-82. doi: 10.1152/ajplung.00345.2014. Epub 2015 Jan 23. Am J Physiol Lung Cell Mol Physiol. 2015. PMID: 25617377 Free PMC article.
Impact with equity: EDCTP and equitable research partnerships.
Makanga M, Beattie P, Jajkowicz D, Nyirenda T, Tanner M, Hankins C. Makanga M, et al. Lancet Glob Health. 2024 Apr;12(4):e552-e554. doi: 10.1016/S2214-109X(24)00002-0. Lancet Glob Health. 2024. PMID: 38485420 Free article. No abstract available.
Translating evidence into global impact: lessons for HIV research and policy development from the AMBITION trial.
Jarvis JN, Chou R, Harrison TS, Lawrence DS, Muthoga C, Mupeli K, Meya DB, Mwandumba HC, Kanyama C, Meintjes G, Leeme TB, Ndhlovu CE, Beattie P, Sued O, Pérez Casas C, Makanga M, Ford N. Jarvis JN, et al. Among authors: makanga m. Lancet Glob Health. 2023 Nov;11(11):e1688-e1690. doi: 10.1016/S2214-109X(23)00412-6. Lancet Glob Health. 2023. PMID: 37858577 Free PMC article. No abstract available.
Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial.
Avihingsanon A, Hughes MD, Salata R, Godfrey C, McCarthy C, Mugyenyi P, Hogg E, Gross R, Cardoso SW, Bukuru A, Makanga M, Badal-Aesen S, Mave V, Ndege BW, Fontain SN, Samaneka W, Secours R, Van Schalkwyk M, Mngqibisa R, Mohapi L, Valencia J, Sugandhavesa P, Montalban E, Munyanga C, Chagomerana M, Santos BR, Kumarasamy N, Kanyama C, Schooley RT, Mellors JW, Wallis CL, Collier AC, Grinsztejn B; A5288 Study team. Avihingsanon A, et al. Among authors: makanga m. J Int AIDS Soc. 2022 Jun;25(6):e25905. doi: 10.1002/jia2.25905. J Int AIDS Soc. 2022. PMID: 36039892 Free PMC article.
42 results